RxDoctor Payments Data

Carl May, MD

Ophthalmology · Hanover, PANPI 1194726836

Payments from drug & device makers

$3,858in general payments, 2019–2025

Across 158 payments — averaging $24.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$2K
  • Alcon$703
  • Sun Pharmaceutical Industries Inc.$319
  • AbbVie$293
  • Bausch & Lomb Americas Inc.$243
  • Amgen$185
  • plus $598 from 12 others

What the payments were for

  • Food & beverage$3,78098%
  • Education$581%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,858 in reported general payments places this provider in the 70th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$378,675
Medicare patients
778
Services billed
2,342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost83$37,790
Prednisolone Acetate557$24,726
XiidraLifitegrast11$19,015
MieboPerfluorohexyloctane/Pf18$14,868
RocklatanNetarsudil Mesylat/Latanoprost29$12,180
Travoprost73$9,632
Cyclosporine26$9,116
CombiganBrimonidine Tartrate/Timolol20$8,885
SimbrinzaBrinzolamide/Brimonidine Tart22$6,490
Ketorolac Tromethamine629$6,338
MoxifloxacinMoxifloxacin Hcl326$5,362
Brimonidine Tartrate119$5,126
Brinzolamide28$4,150
IyuzehLatanoprost/Pf12$3,562
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$2,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$293$46,675103 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$243$33,88329 claims
Aerie Pharmaceuticals, Inc.Rocklatan$48$12,18029 claims
AlconSimbrinza$703$6,49022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Hanover

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →